OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(20)
Publication Date
Release Date
2021
(5)
2025
(4)
2024
(3)
2022
(3)
2020
(2)
2026
(1)
2019
(1)
2016
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.
Not available
S-EPMC7817475
|
biostudies-literature
Cite
Extracting the femtometer structure of strange baryons using the vacuum polarization effect.
Not available
S-EPMC11470094
|
biostudies-literature
Cite
Probing CP symmetry and weak phases with entangled double-strange baryons.
Not available
S-EPMC9159954
|
biostudies-literature
Cite
Ultrahigh-energy gamma-ray emission associated with black hole-jet systems.
Not available
S-EPMC12746838
|
biostudies-literature
Cite
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders.
Not available
S-EPMC7077032
|
biostudies-literature
Cite
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977
|
biostudies-literature
Cite
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774
|
biostudies-literature
Cite
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957
|
biostudies-literature
Cite
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604
|
biostudies-literature
Cite
Observation of charge-parity symmetry breaking in baryon decays.
Not available
S-EPMC12310544
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets